<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Endometriosis: Treatment of pelvic pain</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Endometriosis: Treatment of pelvic pain</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Endometriosis: Treatment of pelvic pain</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Schenken, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Endometriosis, which is characterized by endometrial implants outside of the endometrial cavity, is a chronic disease that requires a lifelong management plan. Despite extensive research, the optimal management of endometriosis and its related symptoms is unclear. This topic will review medical and surgical options for treating pelvic pain caused by endometriosis.</p><p>Other topics related to endometriosis are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7384.html" rel="external">"Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16673.html" rel="external">"Endometriosis: Surgical management of pelvic pain"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7416.html" rel="external">"Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3282.html" rel="external">"Endometriosis: Management of ovarian endometriomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14190.html" rel="external">"Endometriosis of the bladder and ureter"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14189.html" rel="external">"Endometriosis: Clinical manifestations and diagnosis of rectovaginal or bowel disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6687.html" rel="external">"Clinical features, diagnostic approach, and treatment of adults with thoracic endometriosis"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender diverse individuals.</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>Treatment decisions are individualized and consider clinical presentation (eg, pain, infertility, mass), symptom severity, disease extent and location, reproductive desires, patient age, medication side effects, surgical complication rates, and cost. We agree with the American Society for Reproductive Medicine Practice Committee statement that "endometriosis should be viewed as a chronic disease that requires a lifelong management plan with the goal of maximizing the use of medical treatment and avoiding repeated surgical procedures" [<a href="#rid1">1</a>].</p><p>Prior to treatment, all women should have a thorough history and examination. Other sources of pelvic pain are eliminated. (See  <a class="medical medical_review" href="/z/d/html/5467.html" rel="external">"Chronic pelvic pain in adult females: Evaluation"</a>.)</p><p class="headingAnchor" id="H402664116"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>Our treatment plan is based on the severity of the patient's endometriosis-related pain. As noted above, other causes of pelvic pain are excluded. We aim to manage the patient's pain with medical therapy for as long as possible and thus limit the number of surgical interventions.</p><p>For women with mild to moderate pain (eg, pain symptoms that do not cause regular absence from school or work) and no ultrasound evidence of an endometrioma, we prescribe nonsteroidal anti-inflammatory drugs (NSAIDs)  (<a class="graphic graphic_table graphicRef71912" href="/z/d/graphic/71912.html" rel="external">table 1</a>) and continuous hormonal contraceptives  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 2</a>) as the first line of treatment because these therapies are low-risk, have few side effects, and provide relief of symptoms for many women. Women who desire pregnancy can use NSAIDs, although we avoid selective COX-2 inhibitors (<a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">celecoxib</a>, rofecoxib, and valdecoxib) as some studies indicate these drugs can prevent or delay ovulation [<a href="#rid2">2-4</a>]. Management of women with an endometrioma is presented separately. (See <a class="local">'Endometrioma'</a> below and  <a class="medical medical_review" href="/z/d/html/3282.html" rel="external">"Endometriosis: Management of ovarian endometriomas"</a>.)</p><p>While this approach is supported by recommendations from major societies and has theoretical cost efficacy [<a href="#rid1">1,5,6</a>], there are no data supporting superiority of one NSAID or hormonal contraceptive over another. Selection is based on patient preference, availability, and cost.</p><p class="bulletIndent1"><span class="glyph">●</span>In women without medical <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=7383" target="_blank">contraindications</a>, we prefer combined estrogen-progestin contraceptives (pill, patch, or vaginal ring) combined with an NSAID. (See <a class="local">'Estrogen-progestin contraceptives'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For women who cannot or choose not to use estrogen therapy, we prescribe progestin-only contraceptive pills (ie, <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> 0.35 mg taken once daily) with an NSAID. (See <a class="local">'Progestins'</a> below.)</p><p></p><p>We reassess the woman's symptoms after three to four months of combined treatment. Women with adequate symptom improvement are continued on the hormonal therapy/NSAID regimen until pregnancy is desired or the average age of menopause is reached. Women whose symptoms do not improve continue NSAID treatment and are offered a different hormonal combination (eg, other estrogen-progestin contraceptive  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 2</a>), oral <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate 5 mg taken once daily, gestrinone 2.5 mg orally twice weekly [not available in the United States]) or depot <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> 150 mg intramuscularly every three months. Drug selection is based on patient preference, availability, and cost. If the alternative hormonal treatment resolves symptoms, then this regimen is continued until pregnancy is desired or the patient reaches the average age of menopause. While we believe this approach of hormonal suppression and NSAID therapy is the preferred first-line treatment for women with mild to moderate symptoms, it is important to note that initial treatment with a gonadotropin-releasing hormone (GnRH) analog is a reasonable alternative used by some experts (see <a class="local">'Gonadotropin-releasing hormone (GnRH) analogs'</a> below). In one clinical trial, <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a>, a selective estrogen receptor modulator (SERM), did not effectively treat pelvic pain associated with endometriosis [<a href="#rid7">7</a>]; we do not use SERMs to treat pelvic pain.</p><p>Women with more severe symptoms (eg, regularly missing school or work because of pain) or symptoms that do not respond to the above therapies are offered a trial of a GnRH analog or laparoscopy for diagnosis and treatment (if they have not already done so). Similar to society recommendations, we start GnRH agonist and add-back therapy simultaneously [<a href="#rid1">1,6</a>]. This strategy limits bone loss, improves vasomotor symptoms, and improves compliance without reducing efficacy [<a href="#rid1">1,8-11</a>].</p><p>We reserve treatment with aromatase inhibitors for women who continue to have refractory symptoms despite GnRH analog treatment because there are fewer data on long-term use of these agents for endometriosis treatment. (See <a class="local">'Agonists'</a> below and  <a class="medical medical_review" href="/z/d/html/7416.html" rel="external">"Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists", section on 'GnRH with add-back therapy'</a> and <a class="local">'Aromatase inhibitors'</a> below.)</p><p>Women whose pain does not respond to the above medical treatment are offered laparoscopy for diagnosis and treatment. Excision of endometrial implants, endometriomas, and adhesions is performed at the time of surgery. Surgical intervention may be conservative (retain uterus and ovarian tissue) or definitive (removal of the uterus and possibly the ovaries in women who have completed childbearing), depending on the woman's child-bearing plans and age. After surgery, hormonal suppression (usually with continuous oral contraceptives) is started to prevent recurrence of symptoms. (See <a class="local">'Surgical treatment options'</a> below and  <a class="medical medical_review" href="/z/d/html/16673.html" rel="external">"Endometriosis: Surgical management of pelvic pain", section on 'Postoperative care'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">MEDICAL TREATMENT OPTIONS</span><span class="headingEndMark"> — </span>Medical treatment options include nonsteroidal analgesics, hormonal contraceptives, gonadotropin-releasing hormone (GnRH) analogs, and aromatase inhibitors (AI). As there are no data supporting one treatment or treatment combination over another, the treatment choice involves shared decision-making with the patient and is based upon symptom severity, patient preferences, medication side effects, treatment efficacy, contraceptive needs, costs, and availability [<a href="#rid6">6</a>]. (See <a class="local">'Our approach'</a> above.)</p><p>The general advantages and disadvantages of medical treatment of endometriosis-related pelvic pain are listed in the table  (<a class="graphic graphic_table graphicRef69477" href="/z/d/graphic/69477.html" rel="external">table 3</a>). Of note, medical interventions do not improve fertility, diminish endometriomas, or treat complications of deep endometriosis such as ureteral obstruction [<a href="#rid6">6,12</a>]. Women with these problems proceed with therapy targeted at the specific problem. (See <a class="local">'Treatment of special populations'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h2">Nonsteroidal anti-inflammatory drugs</span><span class="headingEndMark"> — </span>Nonsteroidal anti-inflammatory drugs (NSAIDs) effectively treat primary dysmenorrhea  (<a class="graphic graphic_table graphicRef71912" href="/z/d/graphic/71912.html" rel="external">table 1</a>) [<a href="#rid13">13</a>]. NSAIDs are be considered the first-line treatment for pelvic pain, including endometriosis-related pain. However, there are no high-quality data reporting NSAID efficacy in treating pain due to endometriosis, nor have NSAIDs been shown to be superior to other agents or to placebo [<a href="#rid14">14</a>]. Use of NSAIDs is based on their ready availability, low cost, acceptable side-effect profile, and trial data consistently demonstrating effective reduction of primary dysmenorrhea. (See  <a class="medical medical_review" href="/z/d/html/5414.html" rel="external">"Dysmenorrhea in adult females: Treatment"</a>.)</p><p>While NSAIDs are commonly combined with a contraceptive hormonal therapy, women who desire conception can use NSAIDs alone. For women attempting conception, we avoid selective COX-2 inhibitors (<a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">celecoxib</a>, rofecoxib, and valdecoxib) as some studies indicate these drugs can prevent or delay ovulation [<a href="#rid2">2-4</a>]. (See  <a class="medical medical_review" href="/z/d/html/5414.html" rel="external">"Dysmenorrhea in adult females: Treatment", section on 'Nonsteroidal anti-inflammatory drugs'</a>.)</p><p>Adverse events associated with NSAID use are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Estrogen-progestin contraceptives</span><span class="headingEndMark"> — </span>Combined (estrogen and progestin) contraceptives are the first-line treatment for most women with endometriosis-related pain because they can be used long-term, are well-tolerated, are relatively inexpensive and easy to use, and provide contraception and additional benefits including decreasing the risk of ovarian and endometrial cancers [<a href="#rid15">15,16</a>]. While data from randomly assigned trials support estrogen-progestin therapy to reduce pain [<a href="#rid17">17-19</a>], one meta-analysis of two trials of combined oral contraceptive pills concluded that the evidence was insufficient to make a judgment [<a href="#rid20">20</a>]. Study challenges include differing combinations and doses of medications, duration of follow-up, study size and design, and varying tools used to assess pain. Combined estrogen-progestin treatments include combined oral contraceptive pills (COCs), transdermal patches, and vaginal rings  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 2</a>) [<a href="#rid6">6,21,22</a>].</p><p>As no formulation has demonstrated superiority, we typically begin with a COC containing 20 mcg of ethinyl <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">estradiol</a> given in a continuous dose fashion  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 2</a>). While both cyclic and continuous-dose hormonal regimens appear to be effective at reducing endometriosis-related pain [<a href="#rid23">23,24</a>], two systematic reviews (one with meta-analysis) reported that continuous COC regimens were more effective at reducing pain symptoms than cyclic COC regimens [<a href="#rid15">15,25</a>]. Additionally, one trial reported that the efficacy of COC treatment was equivalent to GnRH treatment (<a class="drug drug_general" data-topicid="8500" href="/z/d/drug information/8500.html" rel="external">goserelin</a>) at reducing pelvic pain, but the trial was limited by small sample size (57 women) and relatively short duration (12 months) [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection", section on 'The shared decision-making process'</a> and  <a class="medical medical_review" href="/z/d/html/5423.html" rel="external">"Hormonal contraception for menstrual suppression", section on 'Combined estrogen-progestin methods'</a>.)</p><p>Estrogen-progestin contraceptives are thought to suppress ovarian function and thereby reduce endometriosis disease activity and pain [<a href="#rid26">26</a>]. The purported therapeutic mechanism is decidualization and subsequent atrophy of endometrial tissue [<a href="#rid27">27</a>]. In addition, estrogen-progestin contraceptives may slow progression of disease, although evidence is conflicting [<a href="#rid23">23,28</a>].</p><p>Risks and side effects of estrogen-progestin contraceptives are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns"</a>.)</p><p class="headingAnchor" id="H57629772"><span class="h2">Progestins</span><span class="headingEndMark"> — </span>For women with endometriosis-related pain who are unable to take or prefer to avoid combined estrogen-progestin contraceptives, progestin-only therapy is another treatment option. The progestins most commonly used for the treatment of endometriosis-related pain include the 19-nortestosterone derivatives <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate (5 mg dose) and <a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">dienogest</a> or <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (MPA) [<a href="#rid1">1</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">Norethindrone</a><strong> acetate</strong> – A commonly used regimen of norethindrone acetate is 5 mg by mouth daily, but the dose can be increased to 2.5 to 15 mg daily depending on side effects including breakthrough bleeding [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MPA and </strong><a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">dienogest</a> – In systematic reviews of progestin therapy for pain associated with endometriosis, MPA and dienogest were superior to placebo [<a href="#rid30">30,31</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Depot MPA can be given as 150 mg intramuscular injection every three months or as a 104 mg subcutaneous injection every three months [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">Dienogest</a> can be prescribed as a 2 mg oral pill taken daily or combined with <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">estradiol</a> valerate as part of a multiphasic oral contraceptive pill (commercial name Natazia, only formulation available in United States, and cannot be used in women with contraindications to estrogen treatment) [<a href="#rid33">33</a>]. In our practice, we reserve dienogest for women who do not tolerate <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate because the treatment outcomes appear to be similar [<a href="#rid34">34</a>], but norethindrone acetate is less expensive.</p><p></p><p>Progestins (synthetic progestogens) inhibit endometrial tissue growth by causing initial decidualization and then atrophy [<a href="#rid1">1</a>]. Additional proposed mechanisms of action include suppression of matrix metalloproteinases, a class of enzymes important in the growth and implantation of ectopic endometrium [<a href="#rid27">27</a>], and inhibition of angiogenesis [<a href="#rid35">35</a>]. The choice of progestin depends upon the contraceptive needs of the patient, side-effect profile of the various drugs, and patient preference. (See  <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)"</a> and  <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"</a>.)</p><p>Progestin-only treatments have several advantages compared with other medical therapies. Progestin-only treatment avoids the estrogen-related thromboembolic risk seen with estrogen-containing contraceptives. Compared with the GnRH analogs, high-dose oral progestin treatment is not associated with bone loss and is less expensive. Compared with <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a>, progestins are better tolerated, have no androgenic side effects, and have a less detrimental impact on lipids. (See <a class="local">'Agonists'</a> below and <a class="local">'Danazol'</a> below.)</p><p>Side effects of progestin treatment can include irregular uterine bleeding/spotting, amenorrhea (<a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">dienogest</a>), weight gain, mood changes (eg, depression), and bone loss (specific to long-term use of depot MPA). Additionally, long-term use of <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate can lead to a significant reduction in high-density lipoprotein cholesterol and significant increases in low-density lipoprotein cholesterol and triglycerides; lipid levels are monitored in patients on long-term therapy [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/2036.html" rel="external">"Drugs that affect bone metabolism", section on 'Medroxyprogesterone acetate'</a> and  <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Reduction in bone mineral density'</a>.)</p><p class="headingAnchor" id="H906506824"><span class="h3">Alternate progestin treatment options</span><span class="headingEndMark"> — </span>Alternate progestin treatment options for the treatment of endometriosis-related pain include ethylnorgestrienone (ie, gestrinone, a synthetic steroid with mixed <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> agonist/antagonist effects available in Europe), the <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">etonogestrel implant</a>, and the <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">levonorgestrel intrauterine device</a>. Because data regarding these agents for the treatment of endometriosis-related pain are limited, we prefer progestin therapies reviewed above.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ethylnorgestrienone (ie, gestrinone)</strong> – In a meta-analysis including two small studies, treatment with either gestrinone or <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a> resulted in similar reductions in pain [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">Etonogestrel implant</a> – An observational study of five women and a trial of 41 women reported that the implant was effective for decreasing the intensity of endometriosis-related pain (dyspareunia, dysmenorrhea, nonmenstrual pelvic pain) [<a href="#rid37">37,38</a>]. In the trial, the average decrease in pain was similar in the implant and depot MPA users (68 versus 53 percent, respectively) [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">Levonorgestrel intrauterine device</a><strong> (LNG IUD)</strong> – A review of three trials of the LNG IUD concluded that there was limited but consistent evidence that postoperative LNG IUD use reduced the recurrence of dysmenorrhea in women with surgically confirmed endometriosis [<a href="#rid39">39-41</a>]. For both methods, irregular menstrual bleeding and amenorrhea were common side effects, but no treatment affected bone mineral density or lipid levels [<a href="#rid42">42,43</a>].</p><p></p><p class="headingAnchor" id="H3230410140"><span class="h2">Gonadotropin-releasing hormone (GnRH) analogs</span><span class="headingEndMark"> — </span>GnRH analogs include agonist and antagonist drugs. </p><p class="headingAnchor" id="H8"><span class="h3">Agonists</span><span class="headingEndMark"> — </span>GnRH agonists include <a class="drug drug_general" data-topicid="9673" href="/z/d/drug information/9673.html" rel="external">nafarelin</a>, <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a>, <a class="drug drug_general" data-topicid="8867" href="/z/d/drug information/8867.html" rel="external">buserelin</a>, <a class="drug drug_general" data-topicid="8500" href="/z/d/drug information/8500.html" rel="external">goserelin</a>, and <a class="drug drug_general" data-topicid="10018" href="/z/d/drug information/10018.html" rel="external">triptorelin</a>. A meta-analysis of 41 trials including nearly 5000 women reported that GnRH agonists were more effective than placebo and as effective as other medical therapies (<a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a>, <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a>, COC) for relieving pain [<a href="#rid44">44</a>]. The meta-analysis concluded that the evidence was limited regarding optimal dose and treatment duration and no route of administration appeared superior to others. In a trial comparing GnRH agonists treatment, laparoscopy, and combined medical/surgical treatment, all three groups reported an overall cure rate of ≥50 percent [<a href="#rid45">45</a>].</p><p>Commonly used drug regimens with demonstrated efficacy for improving endometriosis-related symptoms include <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a> acetate 3.75 mg intramuscular injection given monthly, leuprolide acetate 11.25 mg intramuscular injection given every three months, and intranasal <a class="drug drug_general" data-topicid="9673" href="/z/d/drug information/9673.html" rel="external">nafarelin</a> acetate 200 mcg given twice daily [<a href="#rid46">46-48</a>]. Medication selection is driven by availability and cost.</p><p>To minimize the hypoestrogenic side effects of GnRH agonist treatment, we begin add-back therapy at the same time as the GnRH agonist [<a href="#rid1">1,6</a>]. We prefer treatment with oral <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate 5 mg daily but other regimens are reasonable. (See  <a class="medical medical_review" href="/z/d/html/7416.html" rel="external">"Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists", section on 'GnRH with add-back therapy'</a> and <a class="local">'Our approach'</a> above.)</p><p>GnRH agonists bind to receptors in the pituitary gland. Because GnRH analogs have a longer half-life than native GnRH, the pituitary-ovarian axis is down-regulated and hypoestrogenism results [<a href="#rid1">1</a>]. Endometriosis-related pain is likely treated by the induction of amenorrhea and progressive endometrial atrophy [<a href="#rid27">27</a>]. The hypoestrogenic state is the main source of adverse effects, including hot flushes, vaginal dryness, decreased libido, mood swings, headache, and decreased bone density [<a href="#rid49">49</a>]. Negative effects can be reduced by add-back therapy, typically with oral <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate or a combination of estrogen and progestin (ie, COC pill) [<a href="#rid1">1</a>]. When GnRH agonists are used with add-back therapy, side effects are often better tolerated compared with a progestin-only or <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a> treatment. (See  <a class="medical medical_review" href="/z/d/html/7416.html" rel="external">"Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists", section on 'Pharmacology of GnRH agonists'</a> and  <a class="medical medical_review" href="/z/d/html/7416.html" rel="external">"Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists", section on 'GnRH with add-back therapy'</a>.)</p><p>Adverse effects of GnRH agonists are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7416.html" rel="external">"Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists", section on 'Side effects'</a>.)</p><p class="headingAnchor" id="H3307646391"><span class="h3">Antagonists</span><span class="headingEndMark"> — </span>GnRH antagonists (eg, <a class="drug drug_general" data-topicid="118522" href="/z/d/drug information/118522.html" rel="external">elagolix</a>, relugolix) suppress pituitary gonadotropin hormone production and create a hypoestrogenic state [<a href="#rid50">50</a>]. They are a treatment option for patients with endometriosis-related pain who do not respond to NSAIDs, estrogen-progestin contraceptives, or progestins, and they are easier to dose than GnRH agonists (oral versus intramuscular). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comparison with GnRH agonists</strong> – Unlike GnRH agonists, antagonist agents are effective immediately, do not cause an initial surge in luteinizing hormone and follicle stimulating hormone, and do not require 7 to 14 days for GnRH suppression. The antagonists <a class="drug drug_general" data-topicid="118522" href="/z/d/drug information/118522.html" rel="external">elagolix</a> and relugolix are available in oral form [<a href="#rid51">51,52</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of hypoestrogenism</strong> – The GnRH antagonist induces a dose-dependent hypoestrogenic state to inhibit endometriotic cell proliferation. Symptom relief and adverse events such as vasomotor phenomena, vaginal atrophy, and bone loss are also dose-dependent. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> <strong>and adverse effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Elagolix</strong> – <a class="drug drug_general" data-topicid="118522" href="/z/d/drug information/118522.html" rel="external">Elagolix</a> is an oral tablet approved for treatment of moderate-to-severe endometriosis-related pain [<a href="#rid51">51,53</a>]. Elagolix is given alone (ie, without add-back) when used for this indication. Patients who use elagolix to treat fibroid-related heavy menstrual bleeding take elagolix in combination with add-back estrogen and progestin; this is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5478.html" rel="external">"Uterine fibroids (leiomyomas): Treatment overview", section on 'GnRH analogs'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dosing</strong> – It is available in doses of 150 mg (taken once daily for up to 24 months) or 200 mg (taken twice daily for up to six months). We start with the lower dose and increase to the higher dose as needed for patients whose symptoms are not adequately controlled. The higher dose may be required for patients with dyspareunia as part of their symptomatology. The medication is started within seven days of menses. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Contraindications</strong> – Contraindications include pregnancy and hepatic dysfunction (Child-Pugh Class B). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Adverse</strong> effects – These include hot flushes or night sweats as the drug is used without add-back estrogen and progestin. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Relugolix</strong><strong> </strong>– Relugolix has been studied as a combination therapy (<a class="drug drug_general" data-topicid="131735" href="/z/d/drug information/131735.html" rel="external">relugolix-estradiol-norethindrone</a> [norethisterone acetate; 40 mg/1 mg/0.5 mg]) or as monotherapy (40 mg dose for 12 weeks) followed by combination therapy for 12 weeks [<a href="#rid52">52,54,55</a>]. The relative therapeutic contribution of each medication (relugolix, <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">estradiol</a>, <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a>) is unknown. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Limitations of efficacy data</strong> – Direct comparison studies of relugolix combination therapy versus <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> are needed to understand the contribution of each medicine to the clinical effect and assess if combination relugolix therapy has benefits above treatment with norethindrone alone. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Adverse effects</strong> – Relugolix combination therapy has been associated with allergic reactions, including anaphylaxis, urticaria, and angioedema [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting data</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Elagolix</strong><strong> phase-three trial data</strong> – Two phase-three trials compared two different doses of the oral GnRH antagonist <a class="drug drug_general" data-topicid="118522" href="/z/d/drug information/118522.html" rel="external">elagolix</a> (150 mg once daily or 200 mg twice daily) with placebo in patients with endometriosis-related dysmenorrhea and noncyclic pelvic pain [<a href="#rid57">57,58</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Pain reduction</strong> – Patients in both <a class="drug drug_general" data-topicid="118522" href="/z/d/drug information/118522.html" rel="external">elagolix</a> groups reported significantly reduced symptoms and improved quality of life (Endometriosis Health Profile-30 questionnaire) at three months of treatment [<a href="#rid57">57,58</a>]; these reductions persisted at six months of followup [<a href="#rid59">59</a>]. In both trials, at three months, meaningful reductions in dysmenorrhea pain were reported by approximately 44 percent of the low-dose elagolix group, 74 percent of the high-dose elagolix group, and 21 percent of the placebo group. Nonmenstrual pelvic pain was decreased in 50, 56, and 36 percent of women in the low-dose, high-dose, and placebo groups, respectively. Hot flushes were the most common adverse event. However, the improvement in dysmenorrhea in the low-dose elagolix group was modest compared with previously published data on the GnRH agonist depot-leuprolide acetate. (See <a class="local">'Agonists'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Impact on bone mineral density</strong> – At six months, mean changes from baseline in lumbar spine bone density were approximately -0.5, -2.6, and +0.5 percent in the low-dose, high-dose, and placebo groups, respectively. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Adverse events and side effects</strong> – While 72 percent or more of women in all three groups noted an adverse event, side effect-driven discontinuation rates of up to 10 percent were reported in both treatment and placebo groups. Patients in the treatment groups reported significantly more hot flushes (mostly mild to moderate), headache, and insomnia and had higher serum lipids levels (total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides) compared with women receiving placebo. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Relugolix</strong><strong> phase-three trial data </strong>– Two phase-three, multicenter trials, performed across five continents, compared placebo with relugolix combination therapy (<a class="drug drug_general" data-topicid="131735" href="/z/d/drug information/131735.html" rel="external">relugolix-estradiol-norethindrone</a> [norethisterone acetate; 40 mg/1 mg/0.5 mg]) or delayed relugolix combination therapy (relugolix monotherapy, 40 mg dose for 12 weeks, followed by combination therapy for 12 weeks) in individuals with moderate-to-severe endometriosis-related pain [<a href="#rid52">52</a>]. Across the two trials, compared with the placebo group, more patients receiving relugolix reported reductions in dysmenorrhea (75 percent versus 27 to 30 percent) and less nonmenstrual pelvic pain (58 to 66 percent versus 40 to 43 percent) at six months of follow-up. The most common adverse events were headache, nasopharyngitis, and hot flushes. While both treatment groups experienced reductions in bone mineral density compared with placebo, the reductions were less than 1 percent and not considered clinically significant. Both relugolix treatments were also associated with reduced opioid use. Delayed therapy was associated with similar pain reductions but also with more hot flashes and greater loss of bone mineral density. Data comparing relugolix with established treatments for endometriosis-related pain are lacking.</p><p></p><p class="headingAnchor" id="H1694486511"><span class="h2">Danazol</span><span class="headingEndMark"> — </span>While <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a> is effective at treating endometriosis-related pain, it is not commonly used because of androgenic side effects. In a systematic review of five trials, all of which included women with surgically diagnosed endometriosis, six months of danazol treatment was more effective than placebo in relieving endometriosis-related pain [<a href="#rid60">60</a>]. In one of the included studies, the improvement in pain scores persisted at six months after discontinuation of therapy [<a href="#rid61">61</a>]. However, side effects, including acne, muscle cramps, edema, weight gain (5 percent of body weight), spotting, hirsutism, and voice deepening were common and limited the use of danazol [<a href="#rid60">60-62</a>]. When prescribed, danazol is typically given orally in divided doses ranging from 400 to 800 mg daily, generally for six months. Additionally, one systematic review reported symptom relief with vaginal danazol, particularly for women with rectovaginal endometriosis [<a href="#rid63">63</a>].</p><p><a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">Danazol</a> is a derivative of 17 alpha-ethinyltestosterone [<a href="#rid27">27</a>]. It primarily inhibits the luteinizing hormone surge and steroidogenesis, and increases free testosterone levels. Its mechanisms of action include inhibition of pituitary gonadotropin secretion, direct inhibition of ovarian enzymes responsible for estrogen production, and inhibition of endometriotic implant growth.</p><p class="headingAnchor" id="H56701837"><span class="h2">Aromatase inhibitors</span><span class="headingEndMark"> — </span>The author reserves AI treatment for women with severe, refractory, endometriosis-related pain [<a href="#rid64">64,65</a>]. AIs are often used in combination with progestins [<a href="#rid66">66</a>]. Patients are informed that treatment of endometriosis is an off-label use of these medications. Typical treatments include oral <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a> 1 mg once daily or oral <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a> 2.5 mg once daily. These agents appear to regulate local estrogen formation within the endometriotic lesions themselves, in addition to inhibiting estrogen production in the ovary, brain, and periphery (eg, adipose tissue) [<a href="#rid64">64,67</a>].</p><p>The limited supporting data for this approach include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review of eight studies concluded that AI treatment, with or without progestin, COC, or GnRH agonist, significantly reduced pain compared with GnRH agonist alone [<a href="#rid68">68</a>]. Study limitations included only one randomized trial and the combination of AI with various agents. The included trial randomly assigned patients with severe endometriosis to six months of postoperative <a class="drug drug_general" data-topicid="8500" href="/z/d/drug information/8500.html" rel="external">goserelin</a> plus <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a> or goserelin alone [<a href="#rid69">69</a>]. While patients receiving combination therapy reported longer time to symptom recurrence, quality-of-life and bone mass outcomes were similar between groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a nonrandomized trial including 82 women with rectovaginal endometriosis and pain, the combination of <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a> and <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate was more effective in reducing pain and deep dyspareunia than norethindrone acetate alone, but combined treatment was associated with a higher incidence of adverse effects and cost [<a href="#rid70">70</a>]. Additionally, combination therapy did not improve patient satisfaction or reduce recurrence of pain compared with norethindrone alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A trial that randomly assigned a total of 35 patients with rectovaginal endometriosis to either <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a> plus norethisterone acetate or letrozole plus <a class="drug drug_general" data-topicid="10018" href="/z/d/drug information/10018.html" rel="external">triptorelin</a> reported a similar reduction in pain symptoms during treatment [<a href="#rid71">71</a>]. Endometriotic nodules showed a greater reduction in the group receiving letrozole and triptorelin GnRH, but this group also experienced arthralgias, decreased libido, hot flashes, and depression. A statistically significant decrease in bone density was also seen in the triptorelin group.</p><p></p><p>Disadvantages of AIs include bone loss with prolonged use and ovarian follicular cyst development. The AI is prescribed in combination with a GnRH analog or an oral estrogen-progestin contraceptive to suppress follicular development [<a href="#rid72">72</a>]. For women unable to use GnRH analogs or oral estrogen-progestin contraceptives, oral <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate 5 mg per day is another option.</p><p>Side effects of AI treatment are presented separately. (See  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer", section on 'Side effects'</a>.)</p><p class="headingAnchor" id="H467249041"><span class="h2">Neuropathic pain treatments</span><span class="headingEndMark"> — </span>We offer neuropathic pain treatment to women who continue to have pain despite the medical treatment options for endometriosis-related pain listed above. Treatment of neuropathic pain is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/126633.html" rel="external">"Pharmacologic management of chronic non-cancer pain in adults", section on 'Pharmacologic therapy for neuropathic pain, or nociplastic or centralized pain'</a>.)</p><p class="headingAnchor" id="H11364317"><span class="h1">SURGICAL TREATMENT OPTIONS</span><span class="headingEndMark"> — </span>Because of surgery-associated risks, recovery, and upfront cost, medical therapy is typically tried first. Surgical resection of endometriosis or nerve transection procedures are offered to women who do not respond to medical therapy or who have recurrent pain symptoms. Surgical resection provides a histologic diagnosis as well as reduces pain [<a href="#rid1">1,6</a>]. Disadvantages of surgery include risk of injury (especially the bowel and bladder), possible reduction of ovarian reserve if ovarian surgery is performed (eg, ovarian cyst excision), and adhesion formation, in addition to common surgical risks.</p><p>Surgical treatment of endometriosis as well as pre- and postoperative management are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16673.html" rel="external">"Endometriosis: Surgical management of pelvic pain"</a>.)</p><p class="headingAnchor" id="H698359140"><span class="h2">Surgical resection of endometriosis</span><span class="headingEndMark"> — </span>Surgical resection provides a histologic diagnosis and reduces pain by destroying the endometriotic implants [<a href="#rid1">1,6</a>]. Surgical resection can be conservative (treatment of endometriosis lesions by ablation or resection), definitive (hysterectomy, with or without oophorectomy, in addition to resection of endometriosis), or radical (removal of all visible implants at time of surgery). At least one questionnaire study has reported reduced dyspareunia and improved quality of life with radical resection [<a href="#rid73">73</a>]. Choice of surgical treatment is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16673.html" rel="external">"Endometriosis: Surgical management of pelvic pain"</a>.)</p><p class="headingAnchor" id="H56703648"><span class="h2">Nerve transection</span><span class="headingEndMark"> — </span>Nerve transection procedures, including laparoscopic uterosacral nerve ablation (LUNA) and presacral neurectomy (PSN), have been used to treat pelvic pain caused by endometriosis. Limited data suggest that LUNA is not effective [<a href="#rid6">6,74</a>]. PSN may be effective for the treatment of midline pain associated with menses, but the success of the procedure depends, in part, on the experience of the surgeon, and long-term efficacy has not been demonstrated [<a href="#rid1">1,6</a>]. Nerve transection procedures are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5435.html" rel="external">"Chronic pelvic pain in adult females: Treatment", section on 'When to perform additional surgical procedures aimed to reduce pain'</a>.)</p><p class="headingAnchor" id="H58293678"><span class="h1">TREATMENT OF SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H20"><span class="h2">Infertility</span><span class="headingEndMark"> — </span>Women with infertility and pain caused by endometriosis are not candidates for the hormone suppression therapies because hormonal suppression prevents pregnancy and does not improve fertility [<a href="#rid12">12</a>]. The treatment of infertility associated with endometriosis involves a combination of surgery and assisted reproduction technology. We offer nonsteroidal anti-inflammatory drugs to women with pain. A stepwise approach to treatment of infertility in women with endometriosis is presented separately. (See  <a class="medical medical_review" href="/z/d/html/7408.html" rel="external">"Endometriosis: Treatment of infertility in females"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Endometrioma</span><span class="headingEndMark"> — </span>The goals of endometrioma treatment are to relieve symptoms (eg, pain or mass), exclude malignancy, improve subfertility, and preserve ovarian function. Medical therapy does not resolve endometriomas [<a href="#rid1">1,75,76</a>]. Symptomatic or expanding endometriomas are removed laparoscopically. However, surgical removal can diminish ovarian reserve [<a href="#rid77">77,78</a>]. To protect ovarian reserve, asymptomatic and small (≤5 cm) endometriomas can be left in place. Management of ovarian endometriomas is reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/3282.html" rel="external">"Endometriosis: Management of ovarian endometriomas"</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Deep endometriosis</span><span class="headingEndMark"> — </span>Deep infiltrating endometriosis is a term used to describe infiltrative forms of the disease that involve the uterosacral ligaments, rectovaginal septum, bowel, ureters, or bladder. The management of rectovaginal or bowel endometriosis is impacted by the presenting symptoms, location of lesions, and patient preference. At least one study supports expectant management of asymptomatic women with deep endometriosis [<a href="#rid79">79</a>]. For women with bothersome urinary or bowel symptoms (eg, urinary urgency or frequency, dyspareunia, dysmenorrhea, or dyschezia), medical therapy with hormonal suppression is appropriate [<a href="#rid80">80,81</a>]. Surgery is indicated for women with ureteral or bowel obstruction or women whose symptoms do not improve with medical management [<a href="#rid5">5,82</a>]. (See  <a class="medical medical_review" href="/z/d/html/14190.html" rel="external">"Endometriosis of the bladder and ureter"</a> and  <a class="medical medical_review" href="/z/d/html/14189.html" rel="external">"Endometriosis: Clinical manifestations and diagnosis of rectovaginal or bowel disease"</a>.)</p><p class="headingAnchor" id="H1775021786"><span class="h2">Lesions of nonreproductive organs</span><span class="headingEndMark"> — </span>Endometriosis has been reported in the upper abdomen, diaphragm, abdominal wall (umbilicus, surgical scar), perineum (episiotomy or obstetric scar), and thorax [<a href="#rid5">5</a>]. Complications such as pneumothorax are treated as indicated; ovarian suppression can be added to limit disease progression or treat pain.</p><p>Typically, ovarian suppression with gonadotropin-releasing hormone (GnRH) analogs are the first-line agents because they are highly effective at suppressing ovarian hormone production and inhibiting the growth of endometrial tissue [<a href="#rid83">83-93</a>]. Obstruction of the ureter or bowel should be treated surgically; medical therapy is not effective [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/6687.html" rel="external">"Clinical features, diagnostic approach, and treatment of adults with thoracic endometriosis"</a> and  <a class="medical medical_review" href="/z/d/html/14190.html" rel="external">"Endometriosis of the bladder and ureter", section on 'Ureteral endometriosis'</a> and  <a class="medical medical_review" href="/z/d/html/110323.html" rel="external">"Endometriosis: Treatment of rectovaginal and bowel disease", section on 'Treatment considerations'</a>.)</p><p class="headingAnchor" id="H3097268873"><span class="h2">Presumed endometriosis</span><span class="headingEndMark"> — </span>Women with pain from presumed endometriosis can also benefit from the approach detailed above. It is reasonable to begin medical therapy with nonsteroidal anti-inflammatory drugs and hormonal treatment without a definitive diagnosis because these treatments are low risk. However, surgically confirming the diagnosis is preferred before initiating medication with significant side effects, such as GnRH analogs [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/7384.html" rel="external">"Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact"</a> and <a class="local">'Our approach'</a> above.)</p><p class="headingAnchor" id="H3861534139"><span class="h1">COMPLEMENTARY THERAPIES</span></p><p class="headingAnchor" id="H470878327"><span class="h2">Acupuncture</span><span class="headingEndMark"> — </span>In a systematic review of acupuncture for treatment of endometriosis-related pain, only one randomized trial met the inclusion criteria [<a href="#rid94">94</a>]. In that trial (n = 67), auricular acupuncture was significantly more effective than Chinese herbal medicine for treating dysmenorrhea in women with endometriosis [<a href="#rid95">95</a>].</p><p class="headingAnchor" id="H717326888"><span class="h2">Diet</span><span class="headingEndMark"> — </span>There are no dietary recommendations for prevention or treatment of endometriosis. One study reported that a lower risk of developing endometriosis was associated with a high intake of green vegetables and fruit and an increased risk with intake of beef or other red meat or ham [<a href="#rid96">96</a>]. Risk of endometriosis was not associated with alcohol, coffee, fish, and milk. Several studies have addressed the correlation of diet and dysmenorrhea, but not exclusively in patients with endometriosis. (See  <a class="medical medical_review" href="/z/d/html/5414.html" rel="external">"Dysmenorrhea in adult females: Treatment", section on 'Diet and vitamins'</a>.)</p><p class="headingAnchor" id="H2927758084"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109439.html" rel="external">"Society guideline links: Endometriosis"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15431.html" rel="external">"Patient education: Endometriosis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/2174.html" rel="external">"Patient education: Endometriosis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Endometriosis is a chronic disease that requires a lifelong management plan that maximizes medical treatment and avoids repeat surgical intervention. Each treatment plan takes into account the clinical presentation, symptom severity, disease extent and location, reproductive desires, patient age, medication side effects, surgical complication rates, and cost. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptom-based approach</strong> – Our approach to treating endometriosis-related pain treatment is based on the severity of symptoms. Other causes of pelvic pain are excluded prior to treatment. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild to moderate pain</strong> –For patients with mild to moderate pain, we suggest nonsteroidal anti-inflammatory drugs (NSAIDs)  (<a class="graphic graphic_table graphicRef71912" href="/z/d/graphic/71912.html" rel="external">table 1</a>) and continuous hormonal contraceptives  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 2</a>) rather than either agent alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). These therapies are low-risk, have few side effects, are low-cost, and are generally well-tolerated compared with other medical therapies. Patients who wish to conceive can use the NSAID alone. (See <a class="local">'Nonsteroidal anti-inflammatory drugs'</a> above and <a class="local">'Estrogen-progestin contraceptives'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adequate response to initial treatment</strong> – Patients with adequate symptom improvement continue the hormonal therapy/NSAID regimen until pregnancy is desired or the average age of menopause is reached. Those whose symptoms do not improve continue NSAID treatment and are offered an alternate hormonal combination (eg, change to a different estrogen-progestin contraceptive  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 2</a>) or <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate). (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>More</strong> <strong>severe or refractory symptoms</strong> – For patients with more severe symptoms (eg, regularly missing school or work because of pain) or whose symptoms are not adequately controlled with the above treatments, we suggest a trial of a gonadotropin-releasing hormone (GnRH) analog rather than other drugs or surgical resection (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). GnRH analogs include agonists (eg, <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a> acetate) or antagonists (eg, <a class="drug drug_general" data-topicid="118522" href="/z/d/drug information/118522.html" rel="external">elagolix</a>). GnRH analog treatment has demonstrated efficacy without the negative impact on ovarian reserve as with surgery. When used without add-back hormone therapy, adverse effects include menopause-like symptoms and reduced bone density. (See <a class="local">'Gonadotropin-releasing hormone (GnRH) analogs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Continued refractory symptoms</strong> – Patients who continue to have refractory symptoms despite GnRH analog treatment are offered medical therapy with an aromatase inhibitor. (See <a class="local">'Aromatase inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of laparoscopy</strong> – Patients whose pain does not respond to the above treatments are offered laparoscopy for confirmation of the diagnosis and surgical resection. (See <a class="local">'Our approach'</a> above and <a class="local">'Surgical resection of endometriosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infertility</strong> – Patients with endometriosis-associated infertility are treated with a combination of expectant management, surgery, and assisted reproduction techniques. Medical therapy is ineffective. (See <a class="local">'Infertility'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endometrioma</strong> – For patients with symptomatic or expanding endometriomas, laparoscopic excision is performed to treat the associated pain, confirm the diagnosis, exclude malignancy, and prevent complications, such as cyst rupture or ovarian torsion requiring emergency surgery. For women with asymptomatic or small (≤5 cm) endometriomas, the lesions are left in place because surgical excision can decrease ovarian reserve. Medical therapy does not treat endometriomas. (See <a class="local">'Endometrioma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urinary or bowel symptoms</strong> – For patients with bothersome urinary or bowel symptoms (eg, urinary urgency/frequency, dyspareunia, dysmenorrhea, or dyschezia) suggestive of deep endometriosis, medical therapy with hormonal suppression is appropriate. Surgery is indicated for women with ureteral or bowel obstruction or women whose symptoms do not improve with medical management. (See <a class="local">'Deep endometriosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endometriosis beyond the pelvis</strong> – For patients with symptomatic endometriosis of extra-pelvic organs, we prefer ovarian suppression with GnRH analogs because they are highly effective at suppressing ovarian hormone production and inhibiting the growth of endometrial tissue. (See <a class="local">'Lesions of nonreproductive organs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric therapy for pain</strong> – For patients with pain from presumed endometriosis, we begin empiric medical therapy with NSAIDs and hormonal suppression because these treatments are low-risk. However, we prefer to confirm endometriosis with laparoscopy before initiating medication with significant side effects. (See <a class="local">'Presumed endometriosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril 2014; 101:927.</a></li><li><a class="nounderline abstract_t">Pall M, Fridén BE, Brännström M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum Reprod 2001; 16:1323.</a></li><li><a class="nounderline abstract_t">Duffy DM, VandeVoort CA. Maturation and fertilization of nonhuman primate oocytes are compromised by oral administration of a cyclooxygenase-2 inhibitor. Fertil Steril 2011; 95:1256.</a></li><li><a class="nounderline abstract_t">Bata MS, Al-Ramahi M, Salhab AS, et al. Delay of ovulation by meloxicam in healthy cycling volunteers: A placebo-controlled, double-blind, crossover study. J Clin Pharmacol 2006; 46:925.</a></li><li><a class="nounderline abstract_t">Practice bulletin no. 114: management of endometriosis. Obstet Gynecol 2010; 116:223.</a></li><li class="breakAll">ESHRE Guideline Endometriosis. European Society of Human Reproduction and Embryology. February 2022. https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Endometriosis-guideline (Accessed on February 09, 2022).</li><li><a class="nounderline abstract_t">van Hoesel MH, Chen YL, Zheng A, et al. Selective oestrogen receptor modulators (SERMs) for endometriosis. Cochrane Database Syst Rev 2021; 5:CD011169.</a></li><li><a class="nounderline abstract_t">Mäkäräinen L, Rönnberg L, Kauppila A. Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertil Steril 1996; 65:29.</a></li><li><a class="nounderline abstract_t">Bergqvist A, Jacobson J, Harris S. A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecol Endocrinol 1997; 11:187.</a></li><li><a class="nounderline abstract_t">Taskin O, Yalcinoglu AI, Kucuk S, et al. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil Steril 1997; 67:40.</a></li><li><a class="nounderline abstract_t">Moghissi KS, Schlaff WD, Olive DL, et al. Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil Steril 1998; 69:1056.</a></li><li><a class="nounderline abstract_t">Hughes E, Brown J, Collins JJ, et al. Ovulation suppression for endometriosis. Cochrane Database Syst Rev 2007; :CD000155.</a></li><li><a class="nounderline abstract_t">Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010; :CD001751.</a></li><li><a class="nounderline abstract_t">Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2017; 1:CD004753.</a></li><li><a class="nounderline abstract_t">Zorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet 2015; 292:37.</a></li><li><a class="nounderline abstract_t">Bedaiwy MA, Allaire C, Yong P, Alfaraj S. Medical Management of Endometriosis in Patients with Chronic Pelvic Pain. Semin Reprod Med 2017; 35:38.</a></li><li><a class="nounderline abstract_t">Harada T, Kosaka S, Elliesen J, et al. Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial. Fertil Steril 2017; 108:798.</a></li><li><a class="nounderline abstract_t">Guzick DS, Huang LS, Broadman BA, et al. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril 2011; 95:1568.</a></li><li><a class="nounderline abstract_t">Seracchioli R, Mabrouk M, Frascà C, et al. Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertil Steril 2010; 94:464.</a></li><li><a class="nounderline abstract_t">Brown J, Crawford TJ, Datta S, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2018; 5:CD001019.</a></li><li><a class="nounderline abstract_t">Vercellini P, Frontino G, De Giorgi O, et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80:560.</a></li><li><a class="nounderline abstract_t">Vercellini P, Barbara G, Somigliana E, et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril 2010; 93:2150.</a></li><li><a class="nounderline abstract_t">Harada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: A placebo-controlled, double-blind, randomized trial. Fertil Steril 2008; 90:1583.</a></li><li><a class="nounderline abstract_t">Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993; 60:75.</a></li><li><a class="nounderline abstract_t">Muzii L, Di Tucci C, Achilli C, et al. Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis. Am J Obstet Gynecol 2016; 214:203.</a></li><li><a class="nounderline abstract_t">Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ 2014; 348:g1752.</a></li><li><a class="nounderline abstract_t">Olive DL. Medical therapy of endometriosis. Semin Reprod Med 2003; 21:209.</a></li><li><a class="nounderline abstract_t">Vessey MP, Villard-Mackintosh L, Painter R. Epidemiology of endometriosis in women attending family planning clinics. BMJ 1993; 306:182.</a></li><li class="breakAll">US Food and Drug Administration. FDA approved product information. NORETHINDRONE ACETATE - Norethindrone acetate tablet. US National Library of Medicine. Revised March 3, 2017. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92c3793f-60ea-4b20-9e60-c1486520e61a (Accessed on December 01, 2017).</li><li><a class="nounderline abstract_t">Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 2012; :CD002122.</a></li><li><a class="nounderline abstract_t">Andres Mde P, Lopes LA, Baracat EC, Podgaec S. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet 2015; 292:523.</a></li><li class="breakAll">US Food and Drug Administration. FDA approved product information: Medroxyprogesterone acetate injection. Revised April 6, 2016. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=390087a6-f3c3-4f0b-a930-79acf412f153 (Accessed on December 01, 2017).</li><li class="breakAll">US Food and Drug Administration. FDA approved product information. NATAZIA - Estradiol valerate and estradiol valerate/dienogest. US National Library of Medicine. Revised August 5, 2015. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02c91fba-9c47-43ef-ac78-e82369798834 (Accessed on December 01, 2017).</li><li><a class="nounderline abstract_t">Vercellini P, Bracco B, Mosconi P, et al. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril 2016; 105:734.</a></li><li><a class="nounderline abstract_t">Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update 2012; 18:682.</a></li><li class="breakAll">Cirkel U, Schweppe KW, Ochs H, et al. Effects of LHRH agonist therapy in the treatment of endometriosis. In: Gonadotropin Down-regulation in Gynecological Practice, Chadha DR, Willemsen WNP (Eds), Aln R Liss, New York 1986. Vol 25, p.189.</li><li><a class="nounderline abstract_t">Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study. Contraception 2009; 79:29.</a></li><li><a class="nounderline abstract_t">Yisa SB, Okenwa AA, Husemeyer RP. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon). J Fam Plann Reprod Health Care 2005; 31:67.</a></li><li><a class="nounderline abstract_t">Vercellini P, Frontino G, De Giorgi O, et al. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 2003; 80:305.</a></li><li><a class="nounderline abstract_t">Bayoglu Tekin Y, Dilbaz B, Altinbas SK, Dilbaz S. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril 2011; 95:492.</a></li><li><a class="nounderline abstract_t">Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, et al. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol 2012; 119:519.</a></li><li><a class="nounderline abstract_t">Wong AY, Tang LC, Chin RK. Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2010; 50:273.</a></li><li><a class="nounderline abstract_t">Dilbaz B, Ozdegirmenci O, Caliskan E, et al. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception 2010; 81:510.</a></li><li><a class="nounderline abstract_t">Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2010; :CD008475.</a></li><li><a class="nounderline abstract_t">Alkatout I, Mettler L, Beteta C, et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. J Minim Invasive Gynecol 2013; 20:473.</a></li><li class="breakAll">US Food and Drug Administration. FDA approved drug information. Lupron Depot - Leuprolide acetate 3.75 mg. US National Library of Medicine. Revised October 30, 2016. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60aad237-e1da-4705-cbbb-b3ca79e89ad8 (Accessed on March 29, 2016).</li><li class="breakAll">US Food and Drug Administration. FDA approved product information. Synarel - Nafarelin acetate spray. US National Library of Medicine. Revised August 25, 2015. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6 (Accessed on March 29, 2016).</li><li class="breakAll">US Food and Drug Administration. FDA approved product information. Lupron Depot - Leuprolide acetate 11.25 mg. US National Library of Medicine. Revised October 30, 2013. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60aad237-e1da-4705-cbbb-b3ca79e89ad8 (Accessed on March 29, 2016).</li><li><a class="nounderline abstract_t">Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003; :CD001297.</a></li><li><a class="nounderline abstract_t">Bedaiwy MA, Alfaraj S, Yong P, Casper R. New developments in the medical treatment of endometriosis. Fertil Steril 2017; 107:555.</a></li><li class="breakAll">Orlissa-elagolix tablet, film coated. US Food and Drug Administration (FDA) approved product information. Revised Feb, 2021. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on June 21, 2022).</li><li><a class="nounderline abstract_t">Giudice LC, As-Sanie S, Arjona Ferreira JC, et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet 2022; 399:2267.</a></li><li class="breakAll">Elagolix. EMEA-0013230PIP02-12. European Medicines Agency. Nov 2013. https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001323-pip02-12 (Accessed on June 21, 2022).</li><li class="breakAll">MYFEMBREE- relugolix, estradiol hemihydrate, and norethindrone acetate tablet, film coated. US Food and Drug Administration (FDA) approved product information. Revised October, 2021. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on August 08, 2022).</li><li class="breakAll">Myfembree [package insert]. Brisbane, CA: Myovant Sciences, Inc; 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214846s002lbl.pdf (Accessed on August 10, 2022).</li><li class="breakAll">MYFEMBREE- relugolix, estradiol hemihydrate, and norethindrone acetate tablet, film coated. US Food and Drug Administration (FDA) approved product information. Revised Janusary 2023. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on January 31, 2023).</li><li><a class="nounderline abstract_t">Taylor HS, Giudice LC, Lessey BA, et al. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med 2017; 377:28.</a></li><li><a class="nounderline abstract_t">Agarwal SK, Soliman AM, Pokrzywinski RM, et al. Clinically Meaningful Reduction in Dyspareunia Is Associated With Significant Improvements in Health-Related Quality of Life Among Women With Moderate to Severe Pain Associated With Endometriosis: A Pooled Analysis of Two Phase III Trials of Elagolix. J Sex Med 2020; 17:2427.</a></li><li><a class="nounderline abstract_t">Surrey E, Taylor HS, Giudice L, et al. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies. Obstet Gynecol 2018; 132:147.</a></li><li><a class="nounderline abstract_t">Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2007; :CD000068.</a></li><li><a class="nounderline abstract_t">Telimaa S, Puolakka J, Rönnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol 1987; 1:13.</a></li><li><a class="nounderline abstract_t">Boothroyd CV, Lepre F. Permanent voice change resulting from Danazol therapy. Aust N Z J Obstet Gynaecol 1990; 30:275.</a></li><li><a class="nounderline abstract_t">Godin R, Marcoux V. Vaginally Administered Danazol: An Overlooked Option in the Treatment of Rectovaginal Endometriosis? J Obstet Gynaecol Can 2015; 37:1098.</a></li><li><a class="nounderline abstract_t">Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 2006; 85:1307.</a></li><li><a class="nounderline abstract_t">Mousa NA, Bedaiwy MA, Casper RF. Aromatase inhibitors in the treatment of severe endometriosis. Obstet Gynecol 2007; 109:1421.</a></li><li><a class="nounderline abstract_t">ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice. Obstet Gynecol 2018; 131:1.</a></li><li><a class="nounderline abstract_t">Bulun SE, Zeitoun K, Takayama K, et al. Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis. Endocr Relat Cancer 1999; 6:293.</a></li><li><a class="nounderline abstract_t">Nawathe A, Patwardhan S, Yates D, et al. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG 2008; 115:818.</a></li><li><a class="nounderline abstract_t">Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004; 19:160.</a></li><li><a class="nounderline abstract_t">Ferrero S, Camerini G, Seracchioli R, et al. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod 2009; 24:3033.</a></li><li><a class="nounderline abstract_t">Ferrero S, Venturini PL, Gillott DJ, Remorgida V. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial. Reprod Biol Endocrinol 2011; 9:88.</a></li><li><a class="nounderline abstract_t">Amsterdam LL, Gentry W, Jobanputra S, et al. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril 2005; 84:300.</a></li><li><a class="nounderline abstract_t">Fritzer N, Tammaa A, Haas D, et al. When sex is not on fire: a prospective multicentre study evaluating the short-term effects of radical resection of endometriosis on quality of sex life and dyspareunia. Eur J Obstet Gynecol Reprod Biol 2016; 197:36.</a></li><li><a class="nounderline abstract_t">Leonardi M, Armour M, Gibbons T, et al. Surgical interventions for the management of chronic pelvic pain in women. Cochrane Database Syst Rev 2021; 12:CD008212.</a></li><li><a class="nounderline abstract_t">Chapron C, Vercellini P, Barakat H, et al. Management of ovarian endometriomas. Hum Reprod Update 2002; 8:591.</a></li><li><a class="nounderline abstract_t">Alborzi S, Zarei A, Alborzi S, Alborzi M. Management of ovarian endometrioma. Clin Obstet Gynecol 2006; 49:480.</a></li><li><a class="nounderline abstract_t">Benaglia L, Somigliana E, Vighi V, et al. Rate of severe ovarian damage following surgery for endometriomas. Hum Reprod 2010; 25:678.</a></li><li><a class="nounderline abstract_t">Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97:3146.</a></li><li><a class="nounderline abstract_t">Fedele L, Bianchi S, Zanconato G, et al. Is rectovaginal endometriosis a progressive disease? Am J Obstet Gynecol 2004; 191:1539.</a></li><li><a class="nounderline abstract_t">Westney OL, Amundsen CL, McGuire EJ. Bladder endometriosis: conservative management. J Urol 2000; 163:1814.</a></li><li><a class="nounderline abstract_t">Fedele L, Bianchi S, Montefusco S, et al. A gonadotropin-releasing hormone agonist versus a continuous oral contraceptive pill in the treatment of bladder endometriosis. Fertil Steril 2008; 90:183.</a></li><li><a class="nounderline abstract_t">Abrão MS, Petraglia F, Falcone T, et al. Deep endometriosis infiltrating the recto-sigmoid: critical factors to consider before management. Hum Reprod Update 2015; 21:329.</a></li><li><a class="nounderline abstract_t">Alifano M, Jablonski C, Kadiri H, et al. Catamenial and noncatamenial, endometriosis-related or nonendometriosis-related pneumothorax referred for surgery. Am J Respir Crit Care Med 2007; 176:1048.</a></li><li><a class="nounderline abstract_t">Leong AC, Coonar AS, Lang-Lazdunski L. Catamenial pneumothorax: surgical repair of the diaphragm and hormone treatment. Ann R Coll Surg Engl 2006; 88:547.</a></li><li><a class="nounderline abstract_t">Korom S, Canyurt H, Missbach A, et al. Catamenial pneumothorax revisited: clinical approach and systematic review of the literature. J Thorac Cardiovasc Surg 2004; 128:502.</a></li><li><a class="nounderline abstract_t">Joseph J, Sahn SA. Thoracic endometriosis syndrome: new observations from an analysis of 110 cases. Am J Med 1996; 100:164.</a></li><li><a class="nounderline abstract_t">Visouli AN, Darwiche K, Mpakas A, et al. Catamenial pneumothorax: a rare entity? Report of 5 cases and review of the literature. J Thorac Dis 2012; 4 Suppl 1:17.</a></li><li><a class="nounderline abstract_t">Marshall MB, Ahmed Z, Kucharczuk JC, et al. Catamenial pneumothorax: optimal hormonal and surgical management. Eur J Cardiothorac Surg 2005; 27:662.</a></li><li><a class="nounderline abstract_t">Koizumi T, Inagaki H, Takabayashi Y, Kubo K. Successful use of gonadotropin-releasing hormone agonist in a patient with pulmonary endometriosis. Respiration 1999; 66:544.</a></li><li><a class="nounderline abstract_t">Slabbynck H, Laureys M, Impens N, et al. Recurring catamenial pneumothorax treated with a Gn-RH analogue. Chest 1991; 100:851.</a></li><li><a class="nounderline abstract_t">Uemura T, Matsuyama A, Minaguchi H, Ikeda H. Danazol (an antigonadotropin) in the treatment of catamenial pneumothorax. Asia Oceania J Obstet Gynaecol 1985; 11:81.</a></li><li><a class="nounderline abstract_t">Akal M, Kara M. Nonsurgical treatment of a catamenial pneumothorax with a Gn-RH analogue. Respiration 2002; 69:275.</a></li><li><a class="nounderline abstract_t">Attaran S, Bille A, Karenovics W, Lang-Lazdunski L. Videothoracoscopic repair of diaphragm and pleurectomy/abrasion in patients with catamenial pneumothorax: a 9-year experience. Chest 2013; 143:1066.</a></li><li><a class="nounderline abstract_t">Zhu X, Hamilton KD, McNicol ED. Acupuncture for pain in endometriosis. Cochrane Database Syst Rev 2011; :CD007864.</a></li><li><a class="nounderline abstract_t">Xiang D, Situ Y, Liang X, et al. Ear acupuncture therapy for 37 cases of dysmenorrhea due to endometriosis. J Tradit Chin Med 2002; 22:282.</a></li><li><a class="nounderline abstract_t">Parazzini F, Chiaffarino F, Surace M, et al. Selected food intake and risk of endometriosis. Hum Reprod 2004; 19:1755.</a></li></ol></div><div id="topicVersionRevision">Topic 7383 Version 65.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24630080" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Treatment of pelvic pain associated with endometriosis: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11425807" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21236424" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Maturation and fertilization of nonhuman primate oocytes are compromised by oral administration of a cyclooxygenase-2 inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16855077" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Delay of ovulation by meloxicam in healthy cycling volunteers: A placebo-controlled, double-blind, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20567196" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Practice bulletin no. 114: management of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20567196" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Practice bulletin no. 114: management of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33973648" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Selective oestrogen receptor modulators (SERMs) for endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8557151" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9209899" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8986681" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9627292" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636607" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Ovulation suppression for endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091521" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nonsteroidal anti-inflammatory drugs for dysmenorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28114727" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25644508" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28002850" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Medical Management of Endometriosis in Patients with Chronic Pelvic Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28911925" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21300339" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19442968" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29786828" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Oral contraceptives for pain associated with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12969698" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19328469" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18164001" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: A placebo-controlled, double-blind, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8513962" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26364832" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24647161" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12917790" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Medical therapy of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8338516" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Epidemiology of endometriosis in women attending family planning clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8338516" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Epidemiology of endometriosis in women attending family planning clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22419284" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Progestagens and anti-progestagens for pain associated with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25749349" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Dienogest in the treatment of endometriosis: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25749349" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Dienogest in the treatment of endometriosis: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25749349" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Dienogest in the treatment of endometriosis: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26677792" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22718320" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Anti-angiogenic treatment strategies for the therapy of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22718320" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Anti-angiogenic treatment strategies for the therapy of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19041438" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15720856" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12909492" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20883991" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22314873" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20618247" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472118" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21154398" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Gonadotrophin-releasing hormone analogues for pain associated with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23567095" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23567095" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23567095" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23567095" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583930" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28139238" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : New developments in the medical treatment of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28139238" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : New developments in the medical treatment of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35717987" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35717987" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35717987" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35717987" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35717987" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28525302" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32928659" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinically Meaningful Reduction in Dyspareunia Is Associated With Significant Improvements in Health-Related Quality of Life Among Women With Moderate to Severe Pain Associated With Endometriosis: A Pooled Analysis of Two Phase III Trials of Elagolix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29889764" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17943735" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Danazol for pelvic pain associated with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2972167" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2256868" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Permanent voice change resulting from Danazol therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26637082" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Vaginally Administered Danazol: An Overlooked Option in the Treatment of Rectovaginal Endometriosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16647373" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Aromatase inhibitors: the next generation of therapeutics for endometriosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17540816" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Aromatase inhibitors in the treatment of severe endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29794680" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10731122" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18485158" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14688176" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19726448" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21693037" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16084868" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Anastrazole and oral contraceptives: a novel treatment for endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26704015" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : When sex is not on fire: a prospective multicentre study evaluating the short-term effects of radical resection of endometriosis on quality of sex life and dyspareunia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34923620" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Surgical interventions for the management of chronic pelvic pain in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12498427" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Management of ovarian endometriomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885655" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Management of ovarian endometrioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083485" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Rate of severe ovarian damage following surgery for endometriomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22723324" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15547522" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Is rectovaginal endometriosis a progressive disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10799189" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Bladder endometriosis: conservative management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18177868" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A gonadotropin-releasing hormone agonist versus a continuous oral contraceptive pill in the treatment of bladder endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25618908" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Deep endometriosis infiltrating the recto-sigmoid: critical factors to consider before management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17626909" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Catamenial and noncatamenial, endometriosis-related or nonendometriosis-related pneumothorax referred for surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17059714" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Catamenial pneumothorax: surgical repair of the diaphragm and hormone treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15457149" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Catamenial pneumothorax revisited: clinical approach and systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8629650" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Thoracic endometriosis syndrome: new observations from an analysis of 110 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23304438" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Catamenial pneumothorax: a rare entity? Report of 5 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15784370" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Catamenial pneumothorax: optimal hormonal and surgical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10575342" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Successful use of gonadotropin-releasing hormone agonist in a patient with pulmonary endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1832373" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Recurring catamenial pneumothorax treated with a Gn-RH analogue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4015522" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Danazol (an antigonadotropin) in the treatment of catamenial pneumothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12097775" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Nonsurgical treatment of a catamenial pneumothorax with a Gn-RH analogue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23117231" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Videothoracoscopic repair of diaphragm and pleurectomy/abrasion in patients with catamenial pneumothorax: a 9-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21901713" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Acupuncture for pain in endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16579094" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Ear acupuncture therapy for 37 cases of dysmenorrhea due to endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15254009" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Selected food intake and risk of endometriosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
